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Abstract 
Worsening of diabetic retinopathy (DR) is associated with the initiation of effective treatment 
of glycemia in some patients with diabetes. It has been associated with risk factors such as 
poor blood-glucose control and hypertension, and manifests prior to the long-term benefits of 
optimizing glycaemic control. The majority of evidence supports an association of large and 
rapid reductions in blood-glucose levels with early worsening of DR. Despite a general 
awareness of early worsening within the diabetes community, mechanisms to explain the 
phenomenon remain speculative. We provide an overview of early worsening of DR and its 
pathophysiology based on current data. We describe the phenomenon in various settings, 
including in patients receiving insulin or non-insulin-based treatments, those undergoing 
bariatric surgery, and pregnant women. We discuss various mechanisms and theories 
suggested to explain this paradoxical phenomenon, and summarize implications of these in 
clinical practice. 
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The early worsening phenomenon in diabetic retinopathy 
Diabetic retinopathy (DR) is a common complication of diabetes affecting the vasculature in 
the eye and occurring in approximately one-third of patients with diabetes.1,2 It is the leading 
cause of vision loss in the working-age and elderly population.3 Its progression and 
development is associated with a number of risk factors, including long diabetes duration, poor 
glycaemic control, and poorly controlled hypertension.2,3 Deterioration of DR, upon initiation of 
stringent diabetes treatment, is referred to as ‘early worsening’. In this context, the term ‘early’ 
refers to the establishment of good glycaemic control, and not a short duration of diabetes. 
This seemingly paradoxical outcome was first described in the 1980s in patients with type 1 
diabetes, treated intensively with continuous subcutaneous insulin infusion (CSII) versus 
conventional treatment (i.e. short- or intermediate-acting insulin).4-6 In one early report, 18 
patients with long-term (mean, 14.6 years) poorly controlled diabetes showed that changing 
from a period of poor- to tightly-controlled diabetes was detrimental for patients with existing 
DR. In this study, 7 patients had worsening DR, while 4 patients with existing moderate-to-
severe DR had rapid progression of retinopathy within 3 to 6 months of CSII.4 
The timescale over which early worsening has been reported ranges from 3 months up to 3 
years after treatment initiation.7-11 In the Oslo study, early worsening developed after 3 months 
of treatment in half of the patients treated with CSII (n=7/15) or multiple insulin injections 
(n=8/15) compared with none in the conventional treatment group.7 Similarly, in the Kroc 
collaborative study, almost half of the patients receiving CSII (47%) developed early worsening 
by month 8 of treatment (versus 27% in the conventional treatment group).8 In these trials 
early worsening was defined in various ways, including by progression on the Early Treatment 
of Diabetic Retinopathy Study (ETDRS) severity scale – a standardized scale of disease 
severity derived from grading of retinal fundus photographs, which characterizes DR stages 
(also known as the diabetic retinopathy severity scale [DRSS]) 12 – and by fluorescein 
angiograms.7-9  
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While the existence of early worsening is not in doubt, the pathophysiology of this 
phenomenon is not well understood. Furthermore, the circumstances under which it appears 
remain to be fully elucidated. Since its discovery, early worsening has been described in 
patients with type 1 and type 2 diabetes, including those on various diabetic therapies, who 
have had bariatric surgery, and in pregnant women.13 Here we review the current 
understanding of the pathophysiology of early worsening and possible underlying 
mechanisms. We explore the literature related to early worsening of DR in various different 
settings, the microvascular changes that occur, and existing theories that explain early 
worsening. 
Methodology on literature search strategy and selection criteria  
A literature search was conducted using BIOSIS Previews®, Current Contents® Search, 
EMBASE®, and MEDLINE® databases to identify DR-related publications. Search terms used 
are shown in Table 1. Searches covered publication dates from 1 January 2012 to 31 
December 2017. A total of 167 primary and secondary articles and 41 reviews were retrieved 
and assessed for suitability of inclusion. Clinically relevant publications, as decided by authors, 
were also included.  
Articles were considered suitable for inclusion if they covered specific topics, such as factors 
impacting DR progression, the relationship between glycaemic control and long-term diabetes 
outcomes, and the relationship between glycaemic improvement and early or transient 
worsening of DR. Landmark trials for both type 1 and type 2 diabetes were also included.  
Staging of diabetic retinopathy 
DR is a progressive disease comprising several stages including: 1) no DR, in which there are 
no abnormalities; 2) mild non-proliferative DR, in which there are microaneurysms only; 3) 
moderate non-proliferative DR, in which there may be microaneurysms, retinal dot-and-blot 
haemorrhages, hard exudates or cotton wool spots, but no signs of severe non-proliferative 
DR; 4) severe non-proliferative DR, in which there may be intraretinal haemorrhages, definite 
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venous beading, or intraretinal microvascular abnormalities, but no signs of proliferative DR; 
and 5) proliferative DR with neovascularization and/or vitreous or preretinal haemorrhages.3 
This five-stage DR severity score is the standard for measuring DR disease and reflects 
changes in the eye following eye examinations or fundus photography.12 In severe non-
proliferative DR, abnormal new blood vessels grow in response to the hypoxic environment 
caused by capillary occlusion, which worsens ischemia. In proliferative DR the main 
pathogenic factor is retinal hypoxia, which stimulates vascular endothelial growth factor 
(VEGF) production, resulting in retinal neovascularization.3  
Evidence suggests that retinal neurodegeneration is an early process that precedes the 
microvascular complications of the eye.14 This has been reflected in the guidelines from the 
American Diabetes Association, where DR is referred to as a highly specific neurovascular 
complication of diabetes.15 
The pathophysiology of early worsening – mechanism of action 
The definition of early worsening of DR varies across trials, ranging from changes in severity 
to specific morphological changes or clinically significant progression. The definition of 
“worsening” has been recorded as cotton-wool spots/soft exudates, haemorrhages (including 
dot-and-blot haemorrhages), ‘red spots’ or microaneurysms, intraretinal microvascular 
abnormalities (IRMA) and capillary-free areas.6,9,16-18 Cotton-wool spots are lesions caused by 
microvascular perfusion abnormalities and secondary axoplasmic stasis.19 The relationship 
between cotton-wool spots and glycaemic change is unclear. One theory suggests that a 
decrease in retinal blood flow may cause cotton-wool exudates to appear. This leads to an 
insufficient blood supply on the downstream side of arteriosclerotic arterioles. Impaired 
autoregulation may also be involved.9  
In the Kroc Collaboration study subjects in the intensively treated group were characterized 
by increased numbers of soft exudates (cotton-wool spots) and IRMA, compared with those 
in the conventionally treated group, after 8 months. However, at 2 years, the number of soft 
exudates and IRMA were similar in both treatment groups.20 In the STENO study early 
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worsening events were characterized by soft exudates, microaneurysms, and haemorrhages 
at 1 year. In this study, retinal morphology had improved at 2 years.5,9 In the Oslo study, at 3 
months, only subjects in the intensively treated group had significantly more microaneurysms 
and haemorrhages versus baseline.6 However, at 2 years, those in the conventionally treated 
group had significantly more microaneurysms and haemorrhages versus baseline and versus 
the intensively treated group.6 In the landmark Diabetic Control and Complications Trial 
(DCCT), at 4 years compared with baseline, there was more significant progression of DR in 
those with soft exudates and IRMA versus those without. Furthermore, early worsening of DR 
was higher in the intensively versus conventionally treated group and in patients who 
previously had early worsening than those who had not. In the DCCT, the most important 
factors for early worsening were a higher HbA1c level at screening and reduction of this level 
during the first 6 months of treatment.17 This effect was also seen in a study of patients who 
underwent successful pancreas transplantations. The group of patients who experienced early 
worsening had, among other characteristics, a poor pre-transplant glycaemic control and a 
large difference in HbA1c between the pre- and post-transplant periods.21  
Early worsening of DR, from treatment with insulin and other agents including GLP-1RAs, 
suggests a glycaemia-related mechanism of action. However, other possible mechanisms 
should be considered to explain early worsening in patients with diabetes.  
Other potential mechanisms of early worsening 
The role of blood pressure (BP) control in early worsening remains to be clarified. The UK 
Prospective Diabetes Study (UKPDS) reported the effect of BP control on DR progression, 
suggesting that tight BP control may reduce the risk of DR complications. After 1.5 years the 
relative risk of two-step or worse deterioration on the ETDRS scale in those randomized to 
tight BP control was lower versus those with less tight BP control (RR, 0.88; 95% CI, 0.60 to 
1.29).22 At 4.5 years after randomization, there was a significant difference in microaneurysms 
between the tight BP control versus less-tight BP control group (23.3% versus 33.5%, RR 0.7, 
p=0.003). This effect continued to 7.5 years. In addition, although cotton-wool spots increased 
 7 
 
in both groups, there were fewer in the tight BP control group. Fewer patients in the tight BP 
control group, versus less-tight BP control group, had 2-step or more deterioration on the 
ETDRS scale at 4.5 years (RR, 0.75, p=0.02).23 Conversely, in the ADVANCE study, BP 
lowering (or intensive glucose control) did not significantly reduce the incidence and 
progression of clinically significant DR.24 In the ACCORD BP study, in which 1,263 subjects 
with type 2 diabetes were randomized to intensive versus standard antihypertensive therapy, 
BP control had no effect on the rate of progression of DR (adjusted odds ratio, 1.23; 95% CI, 
0.84 to 1.79; p=0.29).25 There was also no reported effect of BP on DR complications in the 
SUSTAIN 6 trial.26 
It has also been suggested that a rapid drop in HbA1c with intensive versus conventional 
treatment lowers intravascular osmotic pressure, creating an osmotic gradient between 
extracelluar and intracellular compartments. This causes water to move from high to low 
osmotic pressure levels, with vessels, such as small vessels in the eye, being low-pressure 
areas that are particularly sensitive. However, this hypothesis is tentative and requires further 
investigation.27  
Early worsening in type 1 diabetes 
A well-known report of early worsening of DR in type 1 diabetes is from the DCCT (Figure 1).17 
This landmark trial documented the frequency, importance of, and risk factors for early 
worsening of DR using intensive insulin treatment versus conventional treatment in patients 
with type 1 diabetes who had no-to-moderate non-proliferative DR. At the 6- and/or 12-month 
visit early worsening was observed in significantly more patients assigned to receive intensive 
(13.1%) versus conventional (7.6%) treatment (p<0.001). DR regression, that is improvement 
of DR, subsequently occurred at the 18-month visit in 51% and 55% of patients, respectively. 
The risk of 3-step (≥3 steps of the ETDRS final scale) or greater progression of DR versus 
baseline was higher in patients with early worsening versus those without (Table 2).17 
Characteristically, subjects with early worsening had a higher HbA1c at baseline and 
experienced greater reductions in HbA1c during the first 6-months of treatment versus those 
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without. However, despite this initial deterioration in DR, intensively treated subjects had 
similar or more favourable outcomes compared with conventionally treated subjects without 
early worsening. Furthermore, after 10 years, once HbA1c levels had become comparable 
between the two treatment groups, the risk of DR progression was still significantly lower in 
subjects that had been treated intensively compared with conventionally treated patients, and 
a beneficial effect persisted for up to 18 years (Table 2).28,29 
The effects on DR of rapid reductions in HbA1c were further shown in a retrospective 24-month 
case–control study, in which people with diabetes and progression of retinopathy (case) were 
compared with people with diabetes and no progression of retinopathy (control). In the case 
group, HbA1c values decreased rapidly approximately 10 to 9 months before the progression 
of retinopathy, whereas the control group HbA1c values did not change during the entire follow-
up period. The relative risk for DR progression with a 1, 2 or 3% decrease in HbA1c for 
approximately 6 months were 1.7, 2.8 and 4.7, respectively (Table 2).30  
The effect of intensive versus conventional glycaemic targets on long-term complications in 
patients with type 1 diabetes was assessed in a Cochrane-based review.31 This review was 
comprised of 12 trials, a total of 2,230 patients, and a mean follow-up across trials ranging 
between one and 6.5 years. Findings showed that intensive versus conventional treatment 
was highly effective in reducing the risk for developing microvascular diabetes complications 
such as DR (6.2% versus 23.2%, relative risk 0.27, 95% CI 0.18 to 0.42; p<0.00001). 
Furthermore, early worsening of DR was evident after only one year of intensive versus 
conventional glucose control (34.7% versus 14.9%; relative risk 2.32; 95% CI 1.16 to 4.63; 
p<0.02).31  
 
Early worsening in type 2 diabetes 
The evidence for early worsening in subjects with type 2 diabetes is limited because many 
large randomized controlled trials, for example the ADVANCE and ACCORD trials, only 
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evaluated the effect of intensive versus conventional therapy on DR progression, assessed 
as retinal change at trial end, rather than as an early outcome.10,24,25,32  
In UKPDS, which was conducted in patients with new-onset type 2 diabetes, and used regular 
in-trial graded photography for retinal assessment the risk of two-step progression of DR 
during the first 3 years was 15.8% with intensive therapy versus 15.3% with conventional 
therapy in newly diagnosed patients with type 2 diabetes treated with either insulin or a 
sulphonylurea, and by 9 years there was a sustained significant protective effect of improved 
control.10 The long-term risk reduction of DR progression was significantly better in the 
intensively (23.0%) versus conventionally (27.8%) treated patients after 6 years’ follow-up 
(p=0.017).10  
Early worsening was also demonstrated in a retrospective case-controlled study in 68 public 
hospital patients with type 2 diabetes, predominantly from ethnic minorities (Latino/other). 
These patients had annual retinal imaging either as part of a case management programme 
or as standard diabetes care.33 An ‘intensive’ group of patients (n=34) with an HbA1c decrease 
of >1.5% was compared with randomly chosen (control) patients (n=34) with minimal HbA1c 
changes over 2 years. In this study, the intensive group had a larger reduction in HbA1c over 
2 years versus the control group (4.0±0.41% versus 0.2±0.11%). Patients in the intensive 
group showed a 22.6% worsening in retinopathy grade progression (p=0.015), while there was 
minimal change from baseline in the control group (p=NS). Change in retinopathy grade was 
significantly different between groups (p=0.02). Furthermore, in the intensive group more eyes 
worsened by ≥1 retinal grade (p=0.0025) and developed sight-threatening retinopathy 
(p=0.003) versus the control group. 33  This study supports DCCT findings that DR is 
significantly worsened in poorly controlled type 2 diabetes after early intensification of 
glycaemic control and a dramatic change in HbA1c.17,33  
As is the case for patients with type 1 diabetes, there is a large body of evidence supporting 
a beneficial effect of tight glycaemic control in the long term for patients with type 2 diabetes; 
the ACCORD eye study, for example, demonstrated reduced incidence or progression of DR. 
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This study investigated whether intensive glycaemic control, combination therapy for 
dyslipidaemia, and intensive blood-pressure control could limit DR in patients with type 2 
diabetes.25 Participants (N=10,251) were randomly assigned to receive either intensive (target 
HbA1c <6.0%/<42 mmol/mol) or conventional (target HbA1c 7.0–7.9%/ 53–63 mmol/mol) 
treatment for glycemia, dyslipidaemia and BP. At 4 years, rates of progression of DR were 
7.3% with intensive glycaemic control versus 10.4% with standard control.25 A follow-on study 
(ACCORDION), 4 years after trial end showed that DR progressed in 5.8% with intensive 
glycaemic control versus 12.7% with standard control (adjusted odds ratio 0.42, 95% CI 0.28 
to 0.63; p<0.0001). Thus, prior intensive glycaemic control continued to reduce DR 
progression, even after study-end when HbA1c levels had become similar in both groups, 8 
years after randomization and approximately 4 years after trial end.34  
Results from a meta-analysis of the ACCORD, UKPDS, Action in Diabetes and Vascular 
Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE), and Veterans 
Administration Diabetes Trial (VADT), in patients with type 2 diabetes, suggest that intensive 
versus conventional glucose control was associated with a 13% risk reduction (HR, 0.87, 95% 
CI 0.76 to 100; p=0·04) in eye events (a composite of requirement for pan-retinal 
photocoagulation therapy or pars plana vitrectomy, development of proliferative retinopathy, 
or progression of DR) after 5 years follow-up.35 
Early worsening with insulin 
Early worsening of DR has historically been associated with the use of insulin therapy. This 
was based on the observed increase in risk of DR progression (defined as an increase of ≥3 
steps on the ETDRS severity scale) in a 6-month phase 3 trial with insulin glargine versus 
human neutral protamine Hagedorn (NPH) insulin. In this study, 7.0% versus 2.7% of patients 
in the insulin glargine versus NPH insulin group had DR progression.36,37 Subsequently, an in 
vitro study showed insulin glargine to have greater binding affinity for the insulin-like growth 
factor 1 (IGF-1) receptor compared with NPH insulin. 38  It was hypothesized that this might 
lead to the increased risk of DR progression with insulin glargine. However, this was disputed 
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by the results of a 5-year trial investigating DR with insulin glargine versus NPH, which showed 
no difference in the rate of DR progression.37 Subsequently, the ORIGIN study found that there 
was no significant difference between insulin glargine and standard of care groups for the 
occurrence of microvascular events.39 
Early worsening with non-insulin therapies 
The evidence for early worsening of DR with non-insulin therapies continues to grow. 
Glucagon-like peptide-one receptor agonists (GLP-1RAs), like exenatide, liraglutide and 
semaglutide, exemplify a non-insulin-therapy drug class associated with increased rates of 
DR complication events, including early worsening of DR;11,26,40-42 although, not all increases 
were significant compared with placebo.41  
In a retrospective cohort study in patients with type 2 diabetes, >6 months’ treatment with 
exenatide resulted in 29.7% (n=49/165) of patients having progression of DR (of which new 
onset was in 16 patients and worsening of pre-existing DR in 33 patients), while in 19.4%, DR 
improved (p<0.005). The proportion of patients with progression of DR was higher with greater 
reductions in HbA1c.43 Follow-up data from this study showed that sustained treatment with 
exenatide resulted in 80% of patients having improved (62%) or stable (18%) DR status after 
a mean 439 days (1.2 years) from the phase-1 screening (initial DR screening was done 234 
days [8 months] from baseline).40 In the LEADER trial, DR complications, defined as the need 
for retinal photocoagulation or treatment with intravitreal agents, vitreous haemorrhage, or the 
onset of diabetes-related blindness, was evaluated in patients with type 2 diabetes and high 
cardiovascular risk. In this study the incidence of DR complications was non-significantly 
higher in patients receiving liraglutide versus placebo (0.6 versus 0.5 events per 100 patient-
years; HR, 1.15 [95% CI, 0.87 to 1.52]; p=0.33).41 Similarly, semaglutide was associated with 
an increased rate of DR complications in SUSTAIN 6, a preapproval trial to evaluate 
cardiovascular and other long-term outcomes in patients with type 2 diabetes.11 DR 
complications were significantly higher in SUSTAIN 6 with semaglutide versus placebo 
(HR, 1.76; 95% CI, 1.11 to 2.78; p=0.02).11  
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It is important to emphasize that both the LEADER and SUSTAIN 6 trials had similar 
methodologic limitations with regards to the design of the DR complications endpoint. Neither 
was designed to assess DR, and based on the DR collection methods used (as part of the 
general evaluation of investigator-reported AEs), it is not possible to draw definitive 
conclusions relating to the increased risk of DR from these trials. For example, standardized 
retinal fundus photography was not included in the LEADER and SUSTAIN 6 study protocols. 
A subsequent SUSTAIN 6 post hoc analysis suggests that the increased risk of DR with 
semaglutide may not be an agent-specific effect, but rather attributable to the rapidity and 
magnitude of HbA1c reduction during the first 16 weeks of treatment in patients with pre-
existing DR, poor glycaemic control at baseline, and treated with insulin (Table 2).26 
Furthermore, it has been hypothesized that the worsening of DR in SUSTAIN 6 may be 
partially accounted for by the inclusion of patients with advanced non-proliferative or 
proliferative DR, in whom semaglutide may have triggered neovascularization. However, there 
is no information available from either in vitro or in vivo studies on the angiogenic effect of 
GLP-1RA in the retina, and further investigation is required.42  
Across the rest of the SUSTAIN phase 3a clinical development programme (SUSTAIN 1 to 5 
and Japan-based trials) and in SUSTAIN 7, in which patients with sight-threatening DR were 
excluded, there was no increase in DR adverse events in patients treated with semaglutide 
versus comparators.26,44 Furthermore, an assessment using the Food and Drug Administration 
Adverse Event Reporting System has shown no evidence that GLP-1RAs are associated with 
adverse events suggestive of DR progression.45 A meta-analysis assessing the effects of 
GLP-1RAs on DR showed that treatment with GLP-1RAs was not associated with a significant 
increase in the incidence of retinopathy (Mantel–Haenszel odds ratio [95% CI] 0.92 [0.74 to 
1.16]; p=0.49). However, this analysis did not evaluate early worsening of DR.46  
In experimental animal models with early-stage DR, systemically and locally administered 
GLP-1RAs prevented neurodegeneration of the retina and protected from diabetes-related 
changes to the retina.47-49 Similarly, DPP4 inhibitors had a protective effect on retinal 
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microvasculature and prevented neurodegeneration and vascular leakage in the diabetic 
retina.50,51 This evidence for a direct beneficial effect of GLP-1RAs on the retina supports the 
hypothesis that early worsening of DR in SUSTAIN 6 may be attributed to rapid improvement 
in glucose control in insulin-treated patients with pre-existing retinopathy, rather than by direct 
retinal toxicity of GLP-1RAs.45,47-49  
Early worsening following bariatric surgery 
The effect of bariatric surgery on DR and early worsening remains debatable. Existing data 
support positive, neutral and negative effects of bariatric surgery on DR.52 The potential risk 
factors for DR progression following bariatric surgery may include DR severity pre-operation, 
magnitude in HbA1c reduction post-surgery and, in some cases, gender and ethnicity.53,54 
Uncontrolled studies suggest that bariatric surgery may contribute to the worsening of pre-
existing DR post surgery.53,55 A meta-analysis of four non-randomized case studies (N=148), 
showed that in patients with DR preoperatively (n=68), 57.4 ± 18.5% patients had no change, 
23.5 ± 18.7% had progression and 19.2% ± 2.9% had an improvement in DR. In patients with 
no preoperative DR (n=80) an average of 92.5 ± 7.4% remained DR free, while 7.5 ± 7.4% 
progressed to DR. The odds ratio for DR progression in patients with versus without 
preoperative DR was 2.77 (95% CI, 1.10 to 6.9, p=0.03).55 However, data such as the time 
points after bariatric surgery when percentage of no change occurred, progression or 
improvements in DR occurred, or how improved DR rate was assessed are important 
considerations when interpreting findings. In a retrospective observational study of patients 
with type 2 diabetes (N=102) to assess whether bariatric surgery prevented DR progression, 
the overall incidence of new retinopathy was 24%. In this study, young male patients with pre-
existing DR and poor preoperative glycaemic control, and who did not have significantly 
improved HbA1c levels post-operatively, were at most risk of DR progression.53 A pilot study in 
patients with type 2 diabetes and morbid obesity showed moderate background DR, or worse, 
increased the risk of DR progression, while minimal or no DR resulted in a low incidence of 
new DR and DR progression in patients.56 Findings from a retrospective, observational study 
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in patients with type 2 diabetes showed that the probability of DR progression (to moderate or 
higher severity) after bariatric surgery was associated with magnitude of HbA1c reduction from 
pre-surgery levels, short postoperative retinal screening duration, severe preoperative DR, 
male gender, and ethnicity.54 
In other studies bariatric surgery has been shown to have no effect on DR deterioration. For 
example, a survey of the Scandinavian Obesity Surgery Registry showed that in 117 patients 
with type 2 diabetes, majority of patients had no DR deterioration post-surgery (mean 16 
months after surgery; method for evaluating DR was not specified). Furthermore, no 
association between preoperative body mass index (BMI), HbA1c or reduction in HbA1c and 
worsening of DR progression was reported.57 
Conversely, some studies have shown an improvement in DR progression following bariatric 
surgery. For example, a meta-analysis of seven controlled studies indicated that bariatric 
surgery prevented new incident cases of retinopathy. However, there were insufficient data to 
support reduced progression or regression of DR.58 Similarly, in a retrospective observational 
cohort study (N=4,683; 40% racial/ethnic minority [Hispanic, non-Hispanic black or other]) 
patients who had type 2 diabetes remission after bariatric surgery had a 29% lower risk of 
microvascular complications, including first occurrence of retinopathy. Furthermore, in patients 
who eventually relapsed, for every year they remained in remission, they experienced a 19% 
risk reduction of microvascular disease versus patients who did not go into remission.59  
Early worsening in pregnancy  
Pregnancy is a risk factor for DR progression and is associated with increased DR prevalence 
and severity versus non-pregnant women with diabetes. The highest risk of DR worsening 
occurs in the second trimester and can persist for up to 12 months postpartum. Factors 
associated with DR progression in pregnancy include diabetes duration, DR severity at 
conception, hyperglycaemic control, anaemia and coexisting hypertension.60 These risk 
factors have been confirmed in a Japan-based study (N=93; of which type 1 diabetes, n=68 
and type 2 diabetes, n=25) in which progression of DR occurred in 17% of patients. In this 
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study, patients with DR progression had significantly longer diabetes duration (p<0.00001), 
presence of DR pre-pregnancy (p<0.00001), and higher BP in the second trimester (p<0.05) 
versus patients who did not have DR progression.61 
Rapid implementation of tight glycaemic control has also been associated with worsening of 
retinopathy in pregnant women with type 1 diabetes.62 Guidelines recommend that pregnant 
women with pre-existing diabetes be offered retinal assessment by examination and fundus 
retinal imaging. In addition they suggest that DR should not be considered a contraindication 
to rapid glycaemic control in women with a high HbA1c in early pregnancy, but rather that 
retinal assessment is essential in such individuals.63  
Theories for the paradoxical early worsening of DR 
Several theories exist to explain the paradoxical worsening of DR, evident in patients with 
diabetes, following rapid and large reductions in blood glucose. However, as there are 
currently no suitable animal models of DR, there are significant limitations associated with 
such theories.  
Osmotic force theory 
Glucose is an osmotically active molecule and can influence water movements. Thus, changes 
in blood glucose concentrations can alter osmotic pressure, which in turn affects water 
retention. Earlier, we described how rapid reductions in blood glucose affect osmotic pressure 
and the extracellular and intravascular areas.27 Although evidence for this theory is limited, 
transient refractive error is associated with tight glycaemic control, relating to the rate of 
reduction in plasma blood glucose. In a study of 14 patients with diabetes (plasma glucose 
≥400 mg/dL [22.2 mmol/L]; HbA1c ≥12.0% [108 mmol/mol]) transient hyperopic change 
occurred in patients who improved control after hyperglycaemia. There was a positive 
correlation between the magnitude of maximum hyperopic change and daily rate of plasma 
glucose reduction over the first 7 days of treatment (p<0.001), the number of days required 
for hyperopia to reach its peak (p<0.001), and the number of days required for the 
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development and resolution of hyperopic changes (p<0.0001).64 This correlation alone, 
however, is insufficient evidence for causation. 
Synergistic hypothesis 
The synergistic hypothesis postulates that early worsening is caused by the synergistic action 
of insulin and VEGF on the blood vessels in the retina, triggering vascular proliferation and 
therefore worsening DR.27 In an in vitro study, insulin was found to increase reactive oxygen 
species (ROS) in bovine retinal endothelial cells. This increased insulin-induced ROS 
production and VEGF expression, in the presence of high glucose, may explain early 
worsening DR (Table 3).65  
Blood-retinal barrier 
Another mechanism suggested to explain transient worsening of DR is that involving a 
breakdown of the blood–brain barrier following intensive insulin therapy. An in vitro study 
demonstrated an increase in VEGF mRNA and protein levels in the retinas of diabetic rats 
following acute intensive insulin therapy. Retinal nuclear extracts from insulin-treated rats had 
high levels of hypoxia-inducible factor-1ɑ (HIF-1ɑ). Thus, acute intensive insulin therapy led 
to blood–retinal barrier breakdown via HIF-1ɑ-mediated increase in retinal VEGF expression, 
resulting in transient DR (Table 3).66  
VEGF hypothesis 
Tight glycaemic control in a hypoxic environment may lead to VEGF upregulation. In a series 
of in vitro experiments in human and bovine retinal cells, lack of both oxygen and glucose led 
to significant upregulation of VEGF production, whereas lack of oxygen but excess glucose 
led to downregulation of VEGF. Sufficient oxygen with excess glucose had no effect on VEGF 
production.67 In rat cells, transient ischaemia followed by retinal reperfusion led to a significant 
increase in VEGF. VEGF expression was linked to vascular permeability.68  
In addition, a study of 26 patients newly diagnosed with type 1 or type 2 diabetes showed that 
in those who experienced blurred vision after starting insulin therapy, this was followed by a 
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transient increase in macular volume and thickness, which is associated with a decrease in 
the circulating soluble VEGF receptor, sFlt-1 (Table 3).69 
Other potential effects of tight glycaemic control 
Although changes in retinal blood flow and haemodynamics are associated with early 
worsening of DR,70,71 the exact nature of these changes is controversial. For example, in 
bovine aortic endothelial cells, mitochondrial ROS (mtROS) production was increased in 
hypoglycaemic conditions as a result of increased fatty acid oxidation. Furthermore, there was 
an increase in pathological retinal neovascularization in recurrent hypoglycaemic conditions 
in streptozotocin (STZ)-induced diabetic control mice versus eMnSOD-Tg (STZ-Tg) mice. 
Blocking fatty acid oxidation led to reduced ROS production, inhibiting disease progression 
and suggesting that hypoglycaemia-induced mtROS production may contribute to early 
worsening of DR (Table 3).70 In another study using human retinal epithelial cells, the rapid 
achievement of good glycaemic control did not trigger an immediate effect on retinal DNA 
methylation-hydroxymethylation machinery associated with DR progression. In this study, 
good glycaemic control for a longer duration, and/or direct targeting of DNA methylation 
improved mitochondrial damage, and could therefore potentially slow DR progression (Table 
3).71 The relationship between hypoglycaemia and ischaemic retinopathy was investigated in 
an in vivo study using Wistar rats. In this study, reduced blood glucose levels or 
hypoglycaemia caused a significant (p<0.001) reduction in vitreous glucose concentration, 
thereby exacerbating ischaemic retinal injury (Table 3).72  
The role of epigenetic modifications in early worsening of DR, following tight glycaemic control, 
remains to be fully investigated.  
 
Conclusions 
Early worsening of DR is a well-described phenomenon evident in patients with type 1 and 
type 2 diabetes, those who have undergone bariatric surgery, or in pregnant women.13 It does 
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not appear to be agent-specific as it has been described in patients receiving treatments 
ranging from intensive insulin therapy, sulphonylureas, thiazolidinediones to GLP-1RAs.4-
6,10,11,26,40,41  
Morphological retinal changes that occur in early worsening include cotton wool spots/soft 
exudates, IRMA, retinal haemorrhages, and progression to severe non-proliferative or 
proliferative forms of DR.3,6,9,16,17 While the mechanism leading to early worsening remains 
unclear, most evidence suggests an association with glycaemic control. The most important 
factors that are linked with early worsening of DR following rapid improvement of 
hyperglycaemia, are a large reduction in HbA1c (<2%) and the severity of pre-existing DR at 
baseline.17,30,33  
Consequently, insulin labels carry a warning of the risk of early worsening of DR with large 
and rapid reductions in HbA1c in patients with diabetes.73 Although a gradual improvement in 
HbA1c is possible with insulin, this may not be possible with treatments such as GLP-1RAs, 
where the improvement in glycaemic control can be rapid and profound. Poorly controlled 
hypertension is another potential risk factor associated with early worsening.3 
Various hypotheses have been proposed to explain early worsening of DR, but all are tentative 
or inconclusive. There are knowledge gaps consequent on the lack of adequate baseline and 
follow-up retinal imaging data in several large-scale studies. Non-clinical studies might help 
address gaps and generate more robust theories, but suitable animal models are limited.  
Early worsening has implications in clinical practice. The American Diabetes Association 
guidelines suggest at least annual eye examinations for patients with DR, while the Royal 
College of Ophthalmologists guidelines recommend annual eye examinations for mild–
moderate DR and every 4–6 months for moderately severe–very severe DR. Guideline 
revisions may be required for patients with DR and poor glycaemic control prior to initiation of 
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highly efficacious antidiabetic medications.15,63 Rigorous methodology for DR assessment in 
future studies evaluating diabetes agents are required.  
Eye status should be assessed in patients at increased ocular risk prior to initiating intensive 
diabetes treatments to achieve glycaemic control and patients should be informed of the risk, 
and reassured that both the transient loss of visual acuity and possible change in retinal 
architecture are small compared with the proven long-term benefits of glycaemic control.  
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Figures and Tables 
 
Figure 1: Cumulative incidence of DR progression (three-step or greater by ETDRS 
criteria) in the DCCT primary prevention cohort.  
 
There was little difference in percentage of patients with retinopathy progression between the INT and CON groups 
over the first 3 years; however, there was a 76% risk reduction for DR progression evident at the conclusion of the 
DCCT after mean follow-up of 6.5 years 28. ©2014 by the American Diabetes Association® Diabetes Care 2014 
Jan; 37(1):17-23. Reprinted with permission from the American Diabetes Association®. 
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Table 1: Search terms used for literature searches in BIOSIS Previews®, Current 
Contents® Search, EMBASE®, and MEDLINE® databases  
 
Set# Search terms Results 
Primary and secondary articles (NOT reviews) 
S5 S4 NOT (rtype.exact("Review")) 167† 
S4 (s1 and s2 and s3) AND pd(20120101-20171231) 184† 
S3 ti,ab((glycemic or glycaemic or "blood glucose" or BG) near/3 (control or 
maintenance or management or improve‡)) 
120361‡ 
S2 MESH.EXACT("Disease Progression") OR EMB.EXACT("disease exacerbation") 
or ti,ab(progression or worsening or exacerbation or aggravat‡) 
2055459‡ 
S1 MJEMB.EXACT("retinopathy") OR MJMESH.EXACT("Diabetic Retinopathy") or 
ti,ab(diabet* near/3 (retinopathy or retinopathia)) 
85482‡ 
Review articles only 
S5 S4 AND (rtype.exact("Review") AND pd(20120101-20171231)) 41† 
S4 s1 and s2 and s3 586† 
S3 ti,ab((glycemic or glycaemic or "blood glucose" or BG) near/3 (control or 
maintenance or management or improve‡)) 
120361‡ 
S2 MESH.EXACT("Disease Progression") OR EMB.EXACT("disease exacerbation") 
or ti,ab(progression or worsening or exacerbation or aggravat‡) 
2055459‡ 
S1 MJEMB.EXACT("retinopathy") OR MJMESH.EXACT("Diabetic Retinopathy") or 
ti,ab(diabet‡ near/3 (retinopathy or retinopathia)) 
85482‡ 
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‡Duplicates were removed from the search, but included in the result count. 
†Duplicates were removed from the search and from the result count. 
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Table 2: Summaries of clinical studies reporting early worsening DR, or associated outcomes  
 
Trial name Trial type; treatment 
regimen; duration 
Patient population and N Key findings relating to diabetic retinopathy and/or 
early worsening 
Reference 
Type 1 diabetes 
Diabetes Control and 
Complications Trial 
(DCCT) 
Multicentre, randomized clinical 
trial; 
INT versus CON therapy;  
Mean follow-up = 6.5 years 
• Type 1 diabetes  
• N=1,441 
• INT: n = 728 
• CON: n = 711 
 
 
 
• INT versus CON therapy reduced the risk of developing DR by 76%  
• Early worsening was observed at the 6 or 12 month visit in 13.1% versus 7.6% 
patients assigned CON versus INT therapy, respectively (p<0.001). 
The DCCT Research 
group 199817 
 
Epidemiology of 
Diabetes Intervention 
and Complications 
(EDIC) 
Observational follow-up of DCCT • Following DCCT, when HbA1c levels in INT and CON groups converged (year 
8, INT, 7.98%; CON, 8.07%), the benefit of early INT persisted with a 53% 
(p<0.0001) reduction in the risk of further retinopathy progression 
• A 56% (p<0.001) risk reduction in development of proliferative DR in INT 
group 
• Severe retinal outcomes and procedures to treat them were reduced by 50% 
in the INT group  
Aiello LP et al., 201428 
18 years follow-up of 
DCCT/EDIC study 
Follow-up of DCCT/EDIC • 39% versus 56% of INT versus CON therapy patients at risk had further 
progression from DCCT closeout (incidence); 46% adjusted risk reduction (CI 
36, 54; p<0.0001) 
Lachin JM, et al., 201529 
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• Overall, fewer former INT group patients continued to be affected by retinal 
complications 18 years after DCCT close-out 
N/A Retrospective case–control 
study 
Diabetes with progression of DR (case) 
and without progression of DR (control) 
N=76 
Case: n=24 
Control group 1 (baseline DR): n=23 
Control group 2 (no baseline DR): n=29 
• HbA1c values decreased rapidly 10 to 9 months before progression of DR in 
case group. HbA1c remained stable during follow-up in control group 
• The relative risks of a 1, 2 and 3% decrease in HbA1c,for about 6 months prior 
to progression of DR were estimated as, respectively, 1.6, 2.4 and 3.8 
Funatsu H, et al., 199230 
Type 2 diabetes 
Veterans Affairs 
Diabetes Trial 
(VADT) 
Post hoc analysis of VADT 
prospective study 
• Poorly controlled type 2 diabetes 
completing 7-field stereo fundus 
photos at baseline and 5 years 
• N=858 
• Odds of DR progression lower by∼40% in those with baseline TC ≥200 mg/dL 
(p=0.007), LDL-C ≥120 mg/dL (p<0.02) or HDL-C ≥40 mg/dL (P<0.007) in INT 
versus standard glycaemic treatment 
• Odds of DR progression lower by ∼40–50% with reductions of TC by ≥40 
mg/dL (p<0.0001), of LDL-C of ≥40 mg/dL (p<0.004), and of TG by ≥60 mg/dL 
(p=0.004) at Year 5 
• INT associated with decreased odds of progression but not with onset of 
retinopathy in those with worse lipid levels at baseline and more improved 
lipid levels during the study 
Azad N, et al., 201632 
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The Action in 
Diabetes and 
Vascular Disease: 
Preterax and 
Diamicron MR 
Controlled Evaluation 
(ADVANCE) Retinal 
Measurements study 
(AdRem) 
Substudy of ADVANCE, 
multicentre, randomised clinical 
trial 
• Type 2 diabetes (aged ≥55 years) 
• N=1,602 
• Compared with standard glucose control (n=611), intensive glucose control 
(n=630) did not reduce (p=0.27) the incidence and progression of retinopathy 
(OR 0.84; 95% CI 0.61 to 1.15) 
• Lower, borderline significant risks of microaneurysms, hard exudates and 
macular oedema observed with intensive glucose control, adjusted for 
baseline retinal haemorrhages 
• BP lowering or intensive glucose control did not significantly reduce the 
incidence and progression of retinopathy 
Beulens J, et al., 200924 
Public hospital study 
(US) 
Retrospective case–control 
study, retinal imaging 
• Type 2 diabetes, minorities 
• ‘Intensive’ HbA1c decrease >1.5% 
(n=34) 
• Minimal HbA1c changes (n=34) 
• Retinopathy grade progressed +0.7 ± 0.25 units from baseline in the intensive 
group (p=0.015), a 22.6% worsening 
• The control group changed minimally from baseline (0.03 ± 0.14 units, p=NS) 
• More eyes worsened by ≥1 retinal grade (p=0.0025) and developed sight-
threatening retinopathy (p=0.003) in the intensive group 
• DR significantly worsened in poorly controlled type 2 diabetes after early 
intensification of glycaemic control and dramatic HbA1c change 
Shurter A, et al., 201333 
UK Prospective 
Diabetes Study 
(UKPDS) 
Prospective study;  
Intensive policy: sulphonylurea 
(chlorpropamide, glibenclamide, 
glipizide) or insulin 
Conventional policy: diet 
• Type 2 diabetes (newly diagnosed) • After 6 years’ follow-up, fewer patients in the intensive versus conventional 
group, had a two-step deterioration in retinopathy 
UK Prospective 
Diabetes Study 
(UKPDS) Group. 199810  
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Kroc Collaborative 
Study Group 
Randomized study (8 months), 2-
year follow-up of DR progression 
(continuous s.c. insulin infusion 
[CSII] versus unchanged 
conventional injection) 
• Type 2 diabetes and mild-to-
moderate DR 
• N=64 
• In type 2 diabetes patients with mild-to-moderate DR, the acceleration in 
activity associated with tightened control is not sustained and does not initiate 
vasoproliferative deterioration in DR 
• No lasting damage results from the initial DR flare in some type 2 diabetes 
patients with mild-to-moderate DR after starting CSII 
Kroc Collaborative 
Study Group, 198820 
UKPDS 69 Prospective study • Type 2 diabetes 19 clinics in UK 
• N=1,148 
• At 1.5 years, in patients with any type of DR at baseline, the RR of two-step 
or worse deterioration on the ETDRS scale in those randomized to tight BP 
control was numerically greater versus those with less tight BP control (RR, 
1.07; 95% CI, 0.60 to 1.90) 
• In the long term, reduction in BP was associated with an improvement in DR 
Matthews DR, et al., 
200423 
 
Collaborators on 
Trials of Lowering 
Glucose (CONTROL) 
group 
Meta-analysis of microvascular 
outcomes in ACCORD, 
ADVANCE, UKPDS and VADT 
• Type 2 diabetes 
• N=27,049 
• Compared with less intensive glucose control, more intensive glucose control 
resulted in an absolute difference of –0·90% (95% CI –1·22 to –0·58) in mean 
HbA1c at completion of follow-up 
• RR reduced by 13% for eye events (HR: 0·87, 0·76 to 1·00; p=0·04) 
• More intensive glucose control over 5 years reduced eye events 
Zoungas S, et al., 
201735 
N/A Phase-1 and subsequent follow-
up study 
GLP-1RA therapy; 
 
• Type 2 diabetes 
• Phase 1: Exenatide treatment 
n=165 
• Follow-up: 
• N=47 
• Phase 1 study: 29.7% (n=49) of patients had progression of DR of whom 96% 
(n=47) had improvement in HbA1c 
o The proportion of patients with progression of DR was higher with 
greater HbA1c reduction 
o The degree of worsening of DR was proportionate to HbA1c reduction 
Varadhan L, et al., 
201143 
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Follow-up data available from 
mean 439 days from Phase 1 
screening 
• Follow-up: 62% (n=24) had an improvement in DR; 18% (n=7) had no 
documented change to DR status 
Varadhan L, et al., 
201440 
Liraglutide Effect and 
Action in 
Diabetes: Evaluation 
of Cardiovascular 
Outcome 
Results (LEADER) 
Multicentre, double-blind, 
placebo-controlled study; 
Median follow-up 3.8 years 
• Type 2 diabetes 
• N=9,340 
• Liraglutide: 
• n=4668 
• Placebo: 
• n=4,672 
• Incidence of DR events was non-significantly higher in the liraglutide versus 
placebo group (0.6 versus 0.5 events per 100 patient-years; HR, 1.15, 95% 
CI, 0.87 to 1.52; p=0.33) 
Marso SP, et al., 201641 
SUSTAIN 6 Multicentre, double-blind, 
placebo-controlled study; 
Median follow-up 2.1 years 
• Type 2 diabetes 
• N=3,297 
• Semaglutide: 
• n=1,648 
• Placebo: 
• n=1,649 
• Incidence of DR events was significantly higher in the semaglutide versus 
placebo group (1.5 versus 0.9 events per 100 patient-years; HR, 1.76, 95% 
CI, 1.11 to 2.78; p=0.02) 
Marso SP, et al., 201611 
N/A Meta-analysis of GLP-1RA RCT 
microvascular effects 
• Type 2 diabetes • GLP1-RAs not associated with a significant increase in the incidence of 
retinopathy (MH-OR [95% CI] 0.92 [0.74 to 1.16]; p=0.49) 
Dicembrini I, et al., 
201746 
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• 37 trials 
• GLP-1RA (n=21,782) 
• Comparator (n=17,296) 
• In subgroup analyses, GLP1-RAs associated with lower risk of retinopathy 
versus sulphonylureas 
• SUSTAIN-6 suggested that treatment with semaglutide could be associated 
with a progression of DR 
Type 2 diabetes and bariatric surgery 
Specialist bariatric 
unit (UK) 
Retrospective observational 
study, following bariatric surgery 
• Type 2 diabetes 
• Post-bariatric surgery 
• N=102 
• 4 years’ follow-up 
• Preoperatively, 68% of patients had no DR versus 30% with background 
retinopathy, 1% pre-proliferative retinopathy and 1% proliferative retinopathy 
• In the first postoperative visit, 19% of patients developed new DR versus 70% 
stable and 11% improved. Proportions did not differ significantly over time 
• Bariatric surgery does not prevent progression of DR 
• Young male patients with pre-existing DR and poor preoperative glycaemic 
control are most at risk of progression 
Chen Y, et al., 201753 
N/A Meta-analysis on impact of 
bariatric surgery on DR 
• Type 2 diabetes 
• DR outcome before and after 
bariatric surgery 
• 4 non-randomised case series 
• N=148 
• Patients with no preoperative DR (n=80), following bariatric surgery, an 
average of 92.5 ± 7.4% remained disease free, while 7.5 ± 7.4% progressed 
to DR 
• Patients with DR preoperatively (n=68), following bariatric surgery, an 
average of 57.4 ± 18.5% had no change, 23.5 ± 18.7% had progression, and 
19.2 ± 2.9% had improvement in their disease 
• Patients with a diagnosis of DR prior to surgery are at increased risk of further 
disease progression 
Cheung D, et al., 201555 
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Scandinavian 
Obesity Surgery 
Registry (SOReg) 
Registry survey on DR outcomes 
before and after GBP 
• Type 2 diabetes and bariatric 
surgery 
• N=117 
• Occurrence of DR before GBP: no DR 62%, mild 26%, moderate 10%, severe 
0% and proliferative DR 2% 
• No significant changes in occurrence of DR after surgery 
• No association between preoperative BMI, HbA1c, or reduction in HbA1c and 
worsening of DR 
Moren A, et al., 201757 
N/A Retrospective pilot analysis of 
electronic hospital records 
• Morbid obesity and type 2 diabetes 
• N=40 pre- and post- surgery DR 
screening 
• Of those without DR pre surgery, 1.5% (n=26) progressed to minimum BDR, 
post-surgery 
• Those with minimum BDR (n=9) pre surgery revealed no progression, with 
55.6% (n=5) showing evidence of regression 
• Risk of progression of DR in those with moderate BDR or worse 
Thomas RL, et al., 
201456 
N/A Retrospective observational 
study 
• Type 2 diabetes and bariatric 
surgery 
• N=318 
• 68.6% had no DR pre-operatively versus 18.9%, 8.5% and 4% with a DR 
grade of minimal, mild or moderate and higher, respectively 
• First post-operative retinal screening results showed that after surgery 73% 
had no change in their DR grade, 11% regressed and 16% progressed 
Murphy R, et al., 201554 
N/A Meta-analysis of bariatric surgery 
and DR 
• Obese type 2 diabetes  
• 7 studies 
• Incident cases of DR were fewer with bariatric surgery than with medical 
treatment 
• Change of DR score (three studies) was not different, while only two studies 
were available on numbers of patients showing progression or regression of 
retinopathy 
Merlotti C, et al., 201758 
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• Bariatric surgery seems to prevent new cases of DR, but available studies are 
not sufficient to support progression or regression of DR 
N/A Retrospective observational 
cohort study (US) of 
microvascular disease (DR, 
neuropathy and/or nephropathy) 
• Type 2 diabetes and bariatric 
surgery 
• N=4,683 
• The rate of incident microvascular disease was primarily due to incidence of 
DR, which occurred at a rate of 8.0%, 18.2%, 28.4%, and 36.5% at 1, 3, 5, 
and 7 years, post-surgery 
• For every additional year of time spent in remission prior to relapse, the risk 
of microvascular disease was reduced by 19% (HR 0.81 [95% CI 0.67 to 
0.99]) versus patients who never remitted 
• Remission of type 2 diabetes after bariatric surgery confers benefits for risk 
of incident microvascular disease even if patients eventually experience a 
relapse of their type 2 diabetes 
Coleman KJ, et al., 
201659 
 
BDR, background diabetic retinopathy; BMI, body mass index; BP, blood pressure; CI, confidence interval; CSII, continuous subcutaneous insulin infusion; DR, diabetic retinopathy; 
CON, conventional; ETDR, Early Treatment of Diabetic Retinopathy Study; GBP, gastric bypass surgery; GLP-1RA, glucagon-like peptide-1 receptor agonist; HR, hazard ratio; INT, 
intensive; LDL-C. low-density lipoprotein cholesterol; MH-OR, Mantel-Haenszel Odds Ratio; N/A, not available; NS, not specified; OR, odds ratio; RCT, randomized controlled trial; RR, 
relative risk; s.c., subcutaneous; TC, total cholesterol; TG, triglycerides.Table 3: Summaries of preclinical studies reporting early worsening, or associated 
outcomes 
Title Study 
population 
Key findings relating to DR and/or early worsening Reference 
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Topical Administration of GLP-1RAs 
Prevents Retinal Neurodegeneration 
in Experimental Diabetes 
Human and db/db mice 
retinas 
• Abundant expression of GLP-1R in the human retina and retinas from db/db mice 
• Systemic administration of liraglutide prevented retinal neurodegeneration (glial activation, neural 
apoptosis, and electroretinographical abnormalities) 
• A similar neuroprotective effect was found using topical administration of native GLP-1 and 
liraglutide, lixisenatide, and exenatide. 
o No reduction in blood glucose levels was observed suggesting that GLP-1R activation 
prevents retinal neurodegeneration  
Hernández C, et al., 201647  
Different effects of low- and high-dose 
insulin on ROS production and VEGF 
expression in bovine retinal microvascular 
endothelial cells (BRECs) in the presence 
of high glucose 
BRECs • High-dose insulin-induced ROS production and VEGF expression in BRECs in the presence of high 
glucose might be one of the reasons for the transient worsening of DR during intensive insulin 
treatment 
Wu H, et al., 201165 
Acute intensive insulin therapy exacerbates 
diabetic blood-retinal barrier (BRB) 
breakdown via hypoxia-inducible factor-1ɑ 
and VEGF 
Diabetic rats • VEGF mRNA and protein levels are increased in retina of diabetic rats intensively treated with 
insulin through hypoxia-inducible factor-1ɑ-mediated increases in retinal VEGF expression, leading 
to BRB breakdown 
• This mechanism explains the transient worsening of DR, specifically BRB breakdown, that follows 
the institution of intensive insulin therapy 
Poulaki V, et al., 200266 
The influence of glucose concentration and 
hypoxia on VEGF secretion by cultured 
retinal cells 
Human and bovine 
retinal cells 
• Lack of both oxygen and glucose led to significant upregulation of VEGF production, whereas, lack 
of oxygen but excess glucose led to downregulation of VEGF 
• Sufficient oxygen with excess glucose had no effect on VEGF production 
Kennedy A and Frank RN, 201167 
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• "Early worsening" of DR may result when diabetic patients with minimal to moderate retinopathy, 
whose retinal circulation and, hence, retinal oxygen supply is compromised, are placed on a "tight" 
glucose control regimen and their major remaining retinal energy source is reduced, with VEGF 
upregulation as a compensatory mechanism 
Effects of Ischemic Preconditioning and 
Bevacizumab on Apoptosis and Vascular 
Permeability Following Retinal Ischemia–
Reperfusion Injury 
Rats • Transient ischaemia followed by retinal reperfusion led to a significant increase in VEGF 
• VEGF expression was linked to vascular permeability 
• IR provides an acute model of ischaemic retinopathy including neurodegeneration and VEGF-
dependent vascular permeability 
Abcouwer SF, et al., 201068 
Effect of intensive insulin therapy on 
macular biometrics, plasma VEGF and its 
soluble receptor, in newly diagnosed 
diabetic patients 
Human • Newly diagnosed patients with blurred vision starting insulin therapy presented with a transient 
increase in macular volume and thickness and decrease in circulating soluble VEGF receptor 
Hernández C, et al., 201069 
Hypoglycaemia-induced retinal 
neurodegeneration is associated with 
mitochondrial ROS (mtROS) production 
caused by fatty acid oxidation 
Bovine aortic 
endothelia cells 
• mtROS production is increased in hypoglycaemic conditions as a result of increased fatty acid 
oxidation 
• Recurrent hypoglycaemia increased ROS production and enhanced pathological retinal 
neovascularization 
• Hypoglycaemia-induced mtROS production may contribute to early worsening of DR 
Kajihara N, et al., 201670 
The Role of DNA Methylation in the 
Metabolic Memory Phenomenon 
Associated With the Continued Progression 
of DR 
Human retinal 
epithelial cells, diabetic 
rat retinas 
• Retinal DNA methylation-hydroxymethylation machinery does not benefit immediately from reversal 
of hyperglycaemia 
Mishra M and Kowluru RA, 201671 
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• Maintenance of good glycaemic control for longer duration, and/or direct targeting DNA methylation 
ameliorates continuous mitochondrial damage, and could retard/halt DR progression 
Hypoglycaemia exacerbates ischaemic 
retinal injury in rats 
Rats and rat retinas • Reduced blood glucose levels or hypoglycaemia caused a significant reduction in vitreous glucose 
concentration, exacerbating ischaemic retinal injury 
Casson RJ. et al,. 200472 
BRB, blood–retinal barrier; BREC, bovine retinal microvascular endothelial cells; DR, diabetic retinopathy; GLP-1RA, glucagon-like peptide-one receptor agonists; VEGF, vascular endothelial growth 
factor; mtROS, mitochondrial reactive oxygen species; ROS, reactive oxygen species. 
 
